anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and system includes an enclosure comprising a plurality of vital signs monitoring devices, a patient chair comprising a plurality of medical sensors, a weight scale, a height measurement device, a video monitor and a first camera for videoconference calls. A second camera is for skin and orifice inspection. A sanitization device sanitizes air and interior surfaces of the cabin. An air management device is operable for sanitizing air entering the cabin. A door has an electrically operated lock. Contaminates on a floor of the cabin are detected. Sanitation of the cabin is initiated. A patient is admitted into the cabin. A videoconference is initiated between the patient and a remote medical practitioner at a medical call center. Data is captured and transmitted to the remote medical practitioner for diagnosis. Prescriptions are processed for the patient. Additional test requests for the patient are processed.
Accumulation of mutant proteins in cells can induce proteinopathies and cause functional damage to organs. Recently, the Cingulin (CGN) protein has been shown to maintain the morphology of cuticular plates of inner ear hair cells and a frameshift mutation in CGN causes autosomal dominant non-syndromic hearing loss. Here, we find that the mutant CGN proteins form insoluble aggregates which accumulate intracellularly and lead to cell death. Expression of the mutant CGN in the inner ear results in severe hair cell death and hearing loss in mice, resembling the auditory phenotype in human patients. Interestingly, a human-specific residue (V1112) in the neopeptide generated by the frameshift mutation is critical for the aggregation and cytotoxicity of the mutant human CGN. Moreover, the expression of heat shock factor 1 (HSF1) decreases the accumulation of insoluble mutant CGN aggregates and rescues cell death. In summary, these findings identify mutant-specific toxic polypeptides as a disease-causing mechanism of the deafness mutation in CGN, which can be targeted by the expression of the cell chaperone response regulator HSF1.
The invention discloses a chicken Marek's disease (MD) Meq gene deleted vaccine strain, a construction method thereof, and an application thereof. The chicken Marek's disease rMS delta Meq gene deleted vaccine strain has a microbe reservation number of CGMCC No. 4612. According to the invention, on a basis of a parent strain which is MDV MS strain, a 468bp base sequence on a front part of a main oncogene is deleted thorough two times of homologous recombination, such that the chicken Marek's disease Meq gene deleted vaccine strain is obtained. The invention also relates to the application of the gene deleted vaccine strain in preparation of medicine used for controlling chicken Marek's disease, and in detection and disgnosis methods used for distinguishing a vaccine strain and a chicken Marek's disease wild strain, wherein the methods are designed aiming at the deleted gene sequence of the gene deleted strain. The gene deleted vaccine strain provided by the invention has good safety and good immuno-protection effect upon chicken Marek's diseases. The vaccine strain can be used for preparing monovalent vaccines or combined vaccines used for controlling chicken Marek's disease.
Hematopoietic stem cell transplantation (HSCT) is associated with significant physical debility. Studies have suggested that physical activity can improve endurance and strength. However, studies have not yet investigated "prehabilitation," exercise before HSCT, to improve functional outcomes. We describe the impact of exercise therapy on physical debility in children undergoing HSCT to inform the implementation of prehabilitation. This review was conducted through a search of the electronic database PubMed. Articles included were those with original research, including randomized control trials, prospective studies, case controls, and retrospective studies. Eleven of the 191 resulting studies met our review criteria. None focused on prehabilitation, but instead on interventions during HSCT. Ten studies showed improvement or maintenance of strength, endurance, stretching, or aerobic fitness. This review shows that exercise therapy can positively affect outcomes in patients undergoing HSCT. Further investigations are needed to determine whether prehabilitation has better results than concurrent exercise.
Hepatitis B Immune Globulin (Human), Nabi-HB, is a sterile solution of immunoglobulin (5 ± 1% protein) containing antibodies to hepatitis B surface antigen (anti-HBs). It is prepared from plasma donated by individuals with high titers of anti-HBs. The plasma is processed using a modified Cohn 6 / Oncley 9 cold-alcohol fractionation process 1,2 with two added viral reduction steps described below. Nabi-HB is formulated in 0.042-0.108 M sodium chloride, 0.10-0.20 M glycine, and 0.005-0.050% polysorbate 80, at pH 5.8-6.5. The product is supplied as a nonturbid sterile liquid in single dose vials and appears as clear to opalescent. It contains no preservative and is intended for single use by the intramuscular route only. 

Each plasma donation used for the manufacture of Nabi-HB is tested for the presence of hepatitis B virus (HBV) surface antigen (HBsAg), human immunodeficiency viruses (HIV) 1/2, and hepatitis C virus (HCV) antibodies. In addition, pooled samples of Source Plasma used in the manufacture of this product are tested by FDA licensed Nucleic Acid Testing (NAT) for HIV and HCV and found to be negative. Investigational NAT for hepatitis A virus (HAV) and HBV is also performed on pooled samples of all Source Plasma used, and found to be negative; however, the significance of a negative result has not been established. Investigational NAT for parvovirus B19 (B19) is also performed on pooled samples of all Source Plasma and the limit for B19 DNA in a manufacturing pool is set not to exceed 10 4 IU/mL. 

The manufacturing steps for Nabi-HB are designed to reduce the risk of transmission of viral disease. The solvent/detergent treatment step, using tri- n-butyl phosphate and Triton ® X-100, is effective in inactivating known enveloped viruses such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) 3. Virus filtration, using a Planova ® 35 nm Virus Filter, is effective in reducing some known enveloped and non-enveloped viruses 4. The inactivation and reduction of known enveloped and non-enveloped model viruses were validated in laboratory studies as summarized in the following table: 

Product potency is expressed in international units (IU) by comparison to the World Health Organization (WHO) standard. Each milliliter (mL) of product contains greater than 312 IU anti-HBs. The potency of each milliliter of Nabi-HB exceeds the potency of anti-HBs in a U.S. reference hepatitis B immune globulin (FDA). The U.S. reference has been tested by Biotest Pharmaceuticals against the WHO standard and found to be equal to 208 IU/mL.
Compounds antagonistic of the pain enhancing effects of prostaglandins are disclosed. The compounds comprise an optionally-substituted A ring with a -CH(R3)N(R2)B-R1 and -OD groups positioned in a 1,2 relationship to one another on ring carbon atoms. The 3-position ring-atom is not substituted. B is an optionally-substituted pyridyl ring and the group R1 is positioned on B in a 1,3 or 1,4 relationship with the -CH(R3)N(R2)B- linking group. R1, R2 and R3 and D can be a number of different organic or halogen moieties. N-oxides of -NR2 and S-oxides of sulphur containing rings are disclosed as are processes for the preparation of the compounds, intermediates in their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents.
PURPOSE:A substance having anti-inflammatory activity is used as a vessel proliferation-suppressing agent effective to suppress the abnormal proliferation of the vessel and useful for the prevention and remedy of tumor, diabetic retinopathy, nodose rheumatism, etc. CONSTITUTION:A substance having anti-inflammatory activity (e.g. predoni solone, acetanilide, salicylic acid, aminopyrine, ibuprofen, etc.) is used as a vessel proliferation-suppressing agent. It has been found that the substance is effective to suppress the abnormal proliferation of the vessel caused by the tumor of experimental animals and the vessel proliferation at the primary focus and the metastatic focus of a cancerous patient, and to suppress the abnormal proliferation of the capillary in the vitreous body of the patient of retinitis proliferans and diabetic retinopathy. It is useful as a vessel proliferation- suppressing agent for the prevention and remedy of retinitis proliferans, nodose rheumatism, psoriasis, diabetic retinopathy, tumor, etc.
Patients with EBV+ lymphoma will receive IV infusion of tabelecleucel or transplant donor-derived EBV-CTLs at 1-5 × 10\^6 T-cells/kg on Days 1, 8, and 15 and will be observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
Disclosed is an isolated binding protein that binds human hepatocyte growth factor (HGF) comprising: (i) an immunoglobulin light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO. 18, a CDRL2 comprising the amino acid sequence of SEQ ID NO. 19, and a CDRL3 comprising the amino acid sequence of SEQ ID NO. 20; and (ii) an immunoglobulin heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO. 15, a CDRH2 comprising the amino acid sequence of SEQ ID NO. 16 or SEQ ID NO. 203, and a CDRH3 comprising the amino acid sequence of SEQ ID NO.17. Also disclosed is the use of the binding protein in the preparation of a medicament for inhibiting or reducing tumor growth in a mammal.
AVANCE-Houston's FRAMEWorks (Family, Relationship, and Marriage Education Works) Project seeks to promote healthy family relationships and economic stability by providing the Survival Skills for Healthy Families (SSHF) curriculum to cohorts of low-income adults. Developed by Family Wellness Associates, SSHF is an evidence-based curriculum delivered through a series of workshops that focus on communication skills, conflict resolution, knowledge of the benefits of marriage, stress and anger management, parenting skills, financial literacy, job and career advancement, and relationship skills to improve family and economic stability. In the past, AVANCE has offered two curriculum delivery models: recurring weekly workshops (standard schedule format) and intensive weekend retreats (compressed schedule format). Each model meets the needs of the target population in different ways, and participants consider factors such as childcare, work/school schedules, weekend availability, and geographic location when choosing their preferred model.

The key goal of this descriptive evaluation is to assess the extent that attitudes and behaviors related to parenting, partner relationships, and financial and job readiness change after participation in the SSHF curriculum. Though the program offers support services and economic stability resources, our analysis will only include outcome changes based on surveys taken at program enrollment, program completion, and one-year post-enrollment. Additionally, a secondary analysis will focus on the ancillary question of whether differences in outcomes exist between in-person and virtual format group participants, and subgroup analyses will be conducted.
Compassion fatigue is the cost of caring for others in emotional pain where the helping professional absorbs the trauma of those they help and cannot detach emotionally at the end of the day. Stressful and perceived unsupportive work environments may leave the caregiver at a heightened risk for compassion fatigue. To study the level of compassion fatigue and compassion satisfaction experienced by mental health nurses. A descriptive, cross-sectional, electronic survey design was utilized. The Professional Quality of Life Scale-5 was used. The study was conducted at a large, urban hospital that exclusively treats patients with mental health and addiction issues located in Ontario, Canada. The sample included all nurses who were listed on the hospital's Email list. All nurses who are displayed on this list are mental health nurses. Analyses were conducted to assess for differences between the characteristics and the subscales of professional quality of life. One hundred and forty-eight mental health nurses completed a questionnaire. The response rate was 21%. Seventy-six percent reported moderate levels of burnout, 59% reported moderate levels of secondary traumatic stress, and 21% reported high levels of compassion satisfaction. Predictors were seen for the characteristics of gender, ethnicity, marital status, area, exposure to violence and support felt. Compassion fatigue has clear implications. Organizations willing to invest in reducing it, have the potential to improve patient outcomes and the well-being of nurses. The majority of mental health nurses reported moderate levels for each of the subscales.
Meperidine Hydrochloride Injection, USP is a sterile solution for intramuscular, subcutaneous or slow intravenous use as a narcotic analgesic.

Each mL of the DOSETTE vial contains meperidine hydrochloride, either 25 mg, 50 mg, 75 mg or 100 mg in Water for Injection. Buffered with acetic acid-sodium acetate. pH 3.5-6.0.

Meperidine hydrochloride is ethyl 1-methyl-4-phenylisonipecotate hydrochloride, a white crystalline substance with a melting point of 186°-189°C. It is readily soluble in water and has a slightly bitter taste. Its structural formula is as follows:
242,323. Clark, G. M., (Knoll & Co., Chemische Fabriks). July 4, 1924. Medicines for internal use; capsules; special shapes and forms; coatings for medicines.- Medicines such as natural or synthetic camphor, santal oil, ethereal oils, alkaloids, and brominated or iodized fats, which will not dissolve in the mixtures of gelatine, glycerine, and water commonly used in making pastilles, are dissolved in an anhydrous mixture of gelatine and glycerine. The pastilles are intended to be swallowed whole, and may be rendered tasteless by means of a layer of non-medicated gelatine, and may be treated with formaldehyde to prevent digestion until the reach the intestine. The non-medicated coating may be applied by coating both sides of a slab of the medicated composition with a solution of gelatine, drying, and stamping out tablets or pearls, or pastilles without a coating may be immersed in alcohol to dissolve the medicament out of the external layer and then washed and dried. Examples are given relating to mixtures of one part gelatine to three parts glycerine medicated respectively with camphor, synthetic camphor, chenopodium oil, camphor and papaverine and a salt of quinine.
The vestibular system receives and conveys information about head motion in space, and is the main human sensory system dedicated to detecting self-motion.The vestibular system plays a crucial role in static and dynamic balance control, stabilizing the head and trunk, especially on unstable surfaces . In terms of postural control and falls, the literature describes a direct association between VOR deficits, gait instability, and falls.The "gain" of the VOR is defined as the change in the eye angle divided by the change in the head angle during the head turn. Under ideal conditions, the gain of the rotational VOR is 1.0, meaning there is a compensatory eye velocity equal to the head velocity and in the opposite direction. In case of a positive vHIT, the VOR gain is decreased and refixating saccades are observed. The video Head Impulse Test measures eye velocity during head rotation. Instant feedback about every single head impulse allows the examiner to apply a set of standardized graded impulses. The system is easy to use in a clinical setting, provides an objective measure of the VOR, and detects both overt and covert catch-up saccades in patients with vestibular loss. Measurements are quick and noninvasive, and the automated analysis software provides instant results.
Severe acute malnutrition (SAM) is the most serious form of acute malnutrition and is associated with high mortality risk among children under 5. While the Community-based Management of Acute Malnutrition (CMAM) approach, recommended for treating cases of uncomplicated SAM, has increased treatment coverage and recovery outcomes, high relapse rates have been reported. Several risk factors for SAM relapse, such as insufficient food intake and high infectious disease burden in the community, have been identified. However, the role of household water, sanitation and hygiene (WASH) conditions remains unclear. This systematic review: (1) assesses the effectiveness of WASH interventions on preventing SAM relapse and (2) identifies WASH-related conditions associated with relapse to SAM among children aged 6-59 months discharged as recovered following SAM CMAM treatment. We performed electronic searches of six databases to identify relevant studies published between 1 January 2000 and 6 November 2023 and assessed their quality. After deduplication, 10,294 documents were screened by title and abstract, with 13 retrieved for full-text screening. We included three studies ranging from low- to medium-quality. One intervention study found that providing a WASH kit during SAM outpatient treatment did not reduce the risk of relapse to SAM. Two observational studies found inconsistent associations between household WASH conditions-unimproved sanitation and unsafe drinking water-and SAM relapse. Despite the paucity of evidence, the hypothesised causal pathways between WASH conditions and the risk of relapse remain plausible. Further evidence is needed to identify interventions for an integrated postdischarge approach to prevent relapse.
Diabetic foot ulcers are a significant and rapidly growing complication of diabetes and its effects on wound healing. Over half of diabetic patients who develop a single ulcer will subsequently develop another ulcer of which the majority will become chronic non-healing ulcers. Over the past decade, the outcomes for patients with ulcers have not improved, despite advances in wound care.These data suggest the importance and necessity of alternative and more effective treatment option for diabetic patients with non-healing ulcers. (Blumberg et al 2012). Stem cell therapy has emerged as a novel therapeutic approach for various diseases including wound repair and tissue regeneration. Mesenchymal stem cells(MSCs) represent an important stem cell population with multipotent capabilities that may have high utility for translational clinical applications. MSCs can differentiate into a variety of cell types, especially fascia originated cells, and provide soluble factors for regeneration of tissues and organs(Şener et al 2015). Adipose tissue is an abundant source of mesenchymal stem cells, which have shown an improved outcome in wound healing studies. Adipose tissue derived stem cells (ASCs )are pluripotent stem cells with the ability to differentiate into different lineages and to secrete paracrine factors initiating tissue regeneration process. The abundant supply of fat tissue, ease of isolation, extensive proliferative capacities ex vivo, and their ability to secrete pro-angiogenic growth factors make them an ideal cell type to use in therapies for the treatment of nonhealing wounds(Hassan et al 2014), However the hostile microenviroment may interfere with viability and efficiency of MSCs injection specially in ischemic tissue , thus increasing needs for new strategies for further improvement of the stem cell therapy of diabetic wounds. Curcumin loaded chitosan nanoparticles into collagen-alginate is a novel biodegradable and biocompatible material that might help a lot in regenerative efficiency in ischemic wound healing
Participants receive 8 sessions of smoking cessation behavioral counseling and 32 weeks of placebo. The placebo comes in a pre-filled pen and is self-injected one time per day into the abdomen, thigh, or upper arm area. The dosing regimen, which is the same as the liraglutide regimen, will begin at 0.6 mg and increase weekly by 0.6 mg until 3 mg is reached (Weeks 1 through 5) and will continue at the 3 mg dose through the end of the study (Week 32).
Complications of extreme preterm birth are the primary cause of mortality in children under the age of five. Bronchopulmonary dysplasia (BPD), the chronic lung disease that follows ventilator and oxygen therapy for acute respiratory failure, is the most common complication of extreme prematurity and contributes to life-long respiratory and neurological impairment. Currently, there is no effective treatment for BPD. The multi-factorial nature of BPD makes it challenging for traditional pharmacological therapies targeting a single pathway to have a major impact on outcome. Mesenchymal stromal cells (MSCs) may provide a promising new treatment avenue due to their pleiotropic effects that may prevent neonatal lung injury while promoting lung (and other organ) growth. A systematic review and meta-analysis of all preclinical studies testing MSCs in neonatal lung injury models provides strong evidence for the lung protective effect of MSCs. Additionally, studies in a large preclinical model of extreme prematurity and chronic lung injury suggest feasibility, safety and short-term hemodynamic benefit of intravenously delivered human umbilical cord tissue-derived MSCs (uc-MSC).

The aim of this study is to establish the safety, maximum feasible dose and feasibility of intravenously delivered allogeneic uc-MSCs in preterm infants at risk of developing BPD. This will be a Phase 1, open-label, single center, dose-escalating trial using a 3+3+3 design.
PCT No. PCT/US95/16434 Sec. 371 Date Sep. 30, 1997 Sec. 102(e) Date Sep. 30, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20205 PCT Pub. Date Jul. 4, 1996The present invention relates to a class of 1,4-dihydrodioxin masked quinone compounds which are useful as DNA or RNA cleaving reagents. These compounds may additionally include moieties which target the compounds to specific base sequences on the DNA or RNA molecule to permit site-specific cleavage. The process for using these compounds in a UV or short wavelength visible light-activated reaction for cleaving DNA, as well as pharmaceutical compositions containing these compounds, are also disclosed.
FIELD: organic chemistry, veterinary science. SUBSTANCE: invention describes new derivatives of triazine of the general formula (I)   where values A, X, R 1 -R 3  are given in p. 1 of the invention claim. Compounds are useful for control of parasitic protozoan pathogens, in part, coccidia and similar parasites and an antiprotozoan composition containing thereof. Invention describes also methods of their synthesis, addition to animal food, method of inhibition of protozoan infection in animals. EFFECT: improved method of synthesis, enhanced effectiveness of compounds. 28 cl, 3 tbl, 106 ex
Young adults, parents/guardians of young people under age 18, and healthcare professionals who work with this population would be intended users of the data management program. The DIDGET World Reports software is used to upload blood glucose results from the DIDGET Blood Glucose Monitoring System so that intended users can identify patterns in their diabetes management.